ATLANTA, May 16, 2006 (PRIMEZONE) -- Market-Pulse.com announces its trade alert for DNAPrint Genomics, Inc. (OTCBB:DNAG). According to Bernard R. Schmitt of Market Pulse, "The company just had excellent news out today regarding its Comput*tional Biology Division completed a pre-clinical, first generation comput*tional model of the characteristics and mechanisms of its PT-401 drug under development for the treatment of anemia." PT-401 is a potential competitor in the EPO market that exceeds $11 billion and is rapidly growing.
DNAPrint Pharmaceuticals is working on the development of "theranostic" genetic test/drug combinations designed to improve a drug's efficacy and reduce potential side effects. PT-401 is the lead drug in DNAPrint's product pipeline. PT-401 is a "Super EPO," a more powerful form of erythropoietin, a well-known drug used for the treatment of anemia.